Kodiak Sciences Inc
KOD7.280USD
+0.630+9.47%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
384.02MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Kodiak Sciences Inc Unternehmen
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy, the cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the cause of blindness in elderly patients. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.
Unternehmensinformationen
BörsenkürzelKOD
Name des UnternehmensKodiak Sciences Inc
IPO-datumOct 04, 2018
CEODr. Victor Perlroth, M.D.
Anzahl der mitarbeiter109
WertpapierartOrdinary Share
GeschäftsjahresendeOct 04
Addresse1250 Page Mill Road
StadtPALO ALTO
BörseNASDAQ Global Market Consolidated
LandUnited States of America
Postleitzahl94304
Telefon16502810850
Websitehttps://kodiak.com/
BörsenkürzelKOD
IPO-datumOct 04, 2018
CEODr. Victor Perlroth, M.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. John A. Borgeson
Mr. John A. Borgeson
Chief Financial Officer, Executive Vice President, Secretary
Chief Financial Officer, Executive Vice President, Secretary
183.32K
+0.63%
Mr. Charles A. (Charlie) Bancroft
Mr. Charles A. (Charlie) Bancroft
Independent Director
Independent Director
25.95K
--
Mr. Robert A. Profusek, J.D.
Mr. Robert A. Profusek, J.D.
Lead Independent Director
Lead Independent Director
10.00K
--
Dr. Richard S. Levy, M.D.
Dr. Richard S. Levy, M.D.
Independent Director
Independent Director
1.00K
--
Dr. Taiyin Yang, Ph.D.
Dr. Taiyin Yang, Ph.D.
Independent Director
Independent Director
--
--
Dr. Victor Perlroth, M.D.
Dr. Victor Perlroth, M.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Dr. Felix J. Baker, Ph.D.
Dr. Felix J. Baker, Ph.D.
Independent Director
Independent Director
--
--
Dr. Bassil I. Dahiyat, Ph.D.
Dr. Bassil I. Dahiyat, Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. John A. Borgeson
Mr. John A. Borgeson
Chief Financial Officer, Executive Vice President, Secretary
Chief Financial Officer, Executive Vice President, Secretary
183.32K
+0.63%
Mr. Charles A. (Charlie) Bancroft
Mr. Charles A. (Charlie) Bancroft
Independent Director
Independent Director
25.95K
--
Mr. Robert A. Profusek, J.D.
Mr. Robert A. Profusek, J.D.
Lead Independent Director
Lead Independent Director
10.00K
--
Dr. Richard S. Levy, M.D.
Dr. Richard S. Levy, M.D.
Independent Director
Independent Director
1.00K
--
Dr. Taiyin Yang, Ph.D.
Dr. Taiyin Yang, Ph.D.
Independent Director
Independent Director
--
--
Dr. Victor Perlroth, M.D.
Dr. Victor Perlroth, M.D.
Chairman of the Board, Chief Executive Officer, Co-Founder
Chairman of the Board, Chief Executive Officer, Co-Founder
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, May 17
Aktualisiert: Sat, May 17
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Baker Bros. Advisors LP
32.81%
BlackRock Institutional Trust Company, N.A.
5.37%
Perlroth (Victor D)
5.11%
Acadian Asset Management LLC
3.69%
The Vanguard Group, Inc.
3.20%
Other
49.82%
Aktionäre
Aktionäre
Anteil
Baker Bros. Advisors LP
32.81%
BlackRock Institutional Trust Company, N.A.
5.37%
Perlroth (Victor D)
5.11%
Acadian Asset Management LLC
3.69%
The Vanguard Group, Inc.
3.20%
Other
49.82%
Aktionärstypen
Aktionäre
Anteil
Hedge Fund
46.97%
Investment Advisor
18.19%
Investment Advisor/Hedge Fund
13.56%
Individual Investor
5.53%
Research Firm
1.50%
Endowment Fund
1.31%
Pension Fund
0.18%
Venture Capital
0.09%
Bank and Trust
0.07%
Other
12.61%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
273
46.04M
87.25%
-8.22M
2025Q1
302
46.32M
87.78%
-8.84M
2024Q4
308
44.88M
85.29%
-7.98M
2024Q3
318
42.74M
81.24%
-12.36M
2024Q2
326
43.49M
82.78%
-12.58M
2024Q1
345
46.64M
88.83%
-7.18M
2023Q4
377
44.39M
84.60%
-13.12M
2023Q3
391
45.97M
87.64%
-8.18M
2023Q2
401
46.07M
88.00%
-6.85M
2023Q1
414
44.84M
85.66%
-7.92M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Baker Bros. Advisors LP
17.31M
32.81%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.83M
5.37%
-21.30K
-0.75%
Mar 31, 2025
Perlroth (Victor D)
2.70M
5.11%
+527.00K
+24.31%
Mar 31, 2025
Acadian Asset Management LLC
1.95M
3.69%
+413.82K
+27.01%
Mar 31, 2025
The Vanguard Group, Inc.
1.69M
3.2%
+6.61K
+0.39%
Mar 31, 2025
Adage Capital Management, L.P.
1.33M
2.51%
+186.18K
+16.34%
Mar 31, 2025
ICONIQ Capital, LLC
1.27M
2.4%
+249.70K
+24.56%
Mar 31, 2025
TCG Crossover Management, LLC
1.15M
2.17%
--
--
Mar 31, 2025
Point72 Asset Management, L.P.
1.07M
2.03%
+548.67K
+104.76%
Mar 31, 2025
Boxer Capital Management, LLC
1.03M
1.96%
+35.00K
+3.50%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
Fidelity Enhanced Small Cap ETF
0.04%
iShares Micro-Cap ETF
0.03%
Avantis US Small Cap Equity ETF
0.02%
Invesco Russell 2000 Dynamic Multifactor ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
Schwab U.S. Small-Cap ETF
0%
Virtus LifeSci Biotech Clinical Trials ETF
0%
ProShares UltraPro Russell2000
0%
Vanguard US Momentum Factor ETF
0%
Mehr Anzeigen
Fidelity Enhanced Small Cap ETF
Anteil0.04%
iShares Micro-Cap ETF
Anteil0.03%
Avantis US Small Cap Equity ETF
Anteil0.02%
Invesco Russell 2000 Dynamic Multifactor ETF
Anteil0.01%
iShares Russell 2000 Value ETF
Anteil0.01%
Invesco RAFI US 1500 Small-Mid ETF
Anteil0.01%
Schwab U.S. Small-Cap ETF
Anteil0%
Virtus LifeSci Biotech Clinical Trials ETF
Anteil0%
ProShares UltraPro Russell2000
Anteil0%
Vanguard US Momentum Factor ETF
Anteil0%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
